BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Descovy (Tenofovir alafenamide/emtricitabine) readouts · Asse
 tMemo
X-WR-CALDESC:Upcoming readouts of Descovy (Tenofovir alafenamide/emtricitab
 ine)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07349758-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 1 readout est.
  (NCT07349758)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 1\, HIV.\
 nStudy: Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy V
 olunteers\nEstimated primary completion: 1 January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073497
 58
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06337032-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 4 readout est.
  (NCT06337032)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 4\, HIV.\
 nStudy: A Study to Provide Continued Access to Study Drug to Children and 
 Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treat
 ments\nEstimated primary completion: June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06337032
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645287-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 2 readout est.
  (NCT07645287)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 2\, HIV.\
 nStudy: A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy
  in Virologically Suppressed People With HIV-1\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teno
 fovir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07645287
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813964-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 3 readout est.
  (NCT05813964)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 3\, HIV.\
 nStudy: Efficacy\, Acceptability and Safety of Event-driven HIV PrEP Using
  TAF/FTC in MSM in Thailand and France.\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofo
 vir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05813964
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055451-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 1 readout est.
  (NCT07055451)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 1\, HIV.\
 nStudy: Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newbor
 ns Exposed to HIV\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 055451
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711223-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 3 readout est.
  (NCT07711223)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 3\, HIV.\
 nStudy: Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir S
 odium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus
  Type 1 (HIV-1)\nEstimated primary completion: 31 August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07711223
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708727-969@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 2/3 readout es
 t. (NCT07708727)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 2/3\, HIV
 .\nStudy: Study of an Injectable Regimen of GS-3242 With Lenacapavir Compa
 red to Biktarvy in People New to HIV-1 Treatment\nEstimated primary comple
 tion: October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 enofovir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07708727
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
